TransMedics Group, Inc. Cash Flow Statement
TMDX / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
TransMedics Group, Inc. generated $193M in operating cash flow and $134M in free cash flow in FY2025. Free cash flow margin was 22.1% of revenue.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $190.3M | $35.5M | -$25.0M | -$36.2M | -$44.2M | -$28.7M | -$9.2M | -$23.8M |
| Depreciation & Amortization | $27.2M | $19.8M | $8.2M | $3.5M | $1.8M | $1.6M | $1.2M | $769.0K |
| Operating Cash Flow | $192.8M | $48.8M | -$13.0M | -$45.8M | -$28.9M | -$30.3M | -$32.3M | -$26.0M |
| Capital Expenditures | $59.3M | $129.7M | $151.8M | $11.9M | $3.5M | $455.0K | $165.0K | $418.0K |
| Free Cash Flow | $133.6M | -$80.9M | -$164.9M | -$57.7M | -$32.4M | -$30.7M | -$32.5M | -$26.4M |
| FCF Margin | 22.1% | -18.3% | -68.2% | -61.8% | -107.0% | -119.8% | -137.5% | - |